Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis

scholarly article published by Alessandro Sette in 2018

Identification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/IAI.00009-18
P932PMC publication ID6105890
P698PubMed publication ID29891545

P50authorSteven C. AlmoQ28197196
Alessandro SetteQ28324161
Cecilia S. Lindestam ArlehamnQ42893016
Steven A PorcelliQ62032714
Scott J GarforthQ96687812
P2093author name stringJohn Chan
William R Jacobs
Alison J Johnson
Jiayong Xu
Steven C Kennedy
Sushma Bharrhan
P2860cites workAllergenicity of mycobacterial ribosomal and ribonucleic acid preparations in mice and guinea pigsQ24649093
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal modelQ24675231
TB vaccine development and the End TB Strategy: importance and current status.Q26748621
Recent advances in the development of vaccines for tuberculosisQ26796440
UCSF Chimera--a visualization system for exploratory research and analysisQ27860666
MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony MethodsQ27860929
Current efforts and future prospects in the development of live mycobacteria as vaccinesQ28087077
Structome analysis of virulent Mycobacterium tuberculosis, which survives with only 700 ribosomes per 0.1 fl of cytoplasmQ28543142
The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunityQ28727776
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trialQ29620144
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomicsQ33218340
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approachQ33326976
The antituberculosis antibiotic capreomycin inhibits protein synthesis by disrupting interaction between ribosomal proteins L12 and L10.Q33622886
Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis.Q33791961
Outcome of tuberculosis treatment and its predictors among HIV infected patients in southwest EthiopiaQ33806776
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adultsQ33950119
Measurement of the rates of synthesis of three components of ribosomes of Mycobacterium fortuitum: a theoretical approach to qRT-PCR experimentationQ33996232
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosisQ34146613
Variation in protection by BCG: implications of and for heterologous immunityQ34288541
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literatureQ34349749
Comparing genomes within the species Mycobacterium tuberculosisQ35033207
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosisQ35033838
ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccinationQ35069386
Effect of Trypsin and Ribonuclease on the Immunogenic Activity of Ribosomes and Ribonucleic Acid Isolated from Mycobacterium tuberculosisQ35181452
A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosisQ35647253
Immune epitope database analysis resourceQ36088427
Ribosome hibernation facilitates tolerance of stationary-phase bacteria to aminoglycosidesQ36158256
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trialQ36287555
Identification of antituberculosis agents that target ribosomal protein interactions using a yeast two-hybrid systemQ36378532
Structure of Ribosomal Silencing Factor Bound to Mycobacterium tuberculosis RibosomeQ36478960
M. tuberculosis T Cell Epitope Analysis Reveals Paucity of Antigenic Variation and Identifies Rare Variable TB AntigensQ36594099
Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populationsQ36628376
Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.Q36888036
IMMUNOGENIC ACTIVITY OF A RIBOSOMAL FRACTION OBTAINED FROM MYCOBACTERIUM TUBERCULOSIS.Q37419107
An expression vector tailored for large-scale, high-throughput purification of recombinant proteinsQ37471293
Evasion and subversion of antigen presentation by Mycobacterium tuberculosisQ37534913
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: part I: the origins and nature of the problemQ37700331
The emergence of extensively drug-resistant tuberculosis: a global health crisis requiring new interventions: Part II: scientific advances that may provide solutionsQ37742687
First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responsesQ37823094
The immunological life cycle of tuberculosisQ38025869
The balance between protective and pathogenic immune responses in the TB-infected lungQ38293027
Prevalence and treatment outcome of extensively drug-resistant tuberculosis plus additional drug resistance from the National Clinical Center for Tuberculosis in China: A five-year reviewQ38627028
Mycobacterium tuberculosis infection and vaccine development.Q38828636
The burden of HIV on Tuberculosis patients in the Volta region of Ghana from 2012 to 2015: implication for Tuberculosis controlQ39445754
Comparison of several culture media used for studies on mycobacteriophages (Plates XII-XIV)Q39601879
Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosisQ39842246
Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4+ T CellsQ40361036
Mechanism and rates of exchange of L7/L12 between ribosomes and the effects of binding EF-G.Q40744224
Status of vaccine research and development of vaccines for tuberculosisQ40757121
Reprogramming the T Cell Response to TuberculosisQ40829662
Demonstration in tissue culture of lymphocyte-mediated immunity to tuberculosis.Q40884282
Zinc regulates a switch between primary and alternative S18 ribosomal proteins in Mycobacterium tuberculosisQ41096097
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adultsQ41148040
Tuberculosis vaccines: time for a global strategyQ41463414
Ribosome degradation in growing bacteriaQ41945677
Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiationQ42226870
The dormancy regulator DosR controls ribosome stability in hypoxic mycobacteria.Q42227117
Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cellsQ42262934
IFNγ/TNFα specific-cells and effector memory phenotype associate with active tuberculosisQ42272434
The Complete Structure of the Mycobacterium smegmatis 70S Ribosome.Q50904778
Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimenQ57100109
Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active diseaseQ58074694
The relationship between sedimentation value and immunogenic acitivity of mycobacterial ribonucleic acidQ69380568
Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette-GúerinQ78164042
The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humansQ84197648
HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortalityQ84734382
P433issue9
P407language of work or nameEnglishQ1860
P921main subjectimmunologyQ101929
parasitologyQ180502
infectious diseaseQ18123741
P577publication date2018-09-01
P1433published inInfection and ImmunityQ6029193
P1476titleIdentification of Mycobacterial Ribosomal Proteins as Targets for CD4 T Cells That Enhance Protective Immunity in Tuberculosis
P478volume86

Reverse relations

Q59800431A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussiscites workP2860

Search more.